Treeline Biosciences is a precision-oncology drug discovery company that integrates wet-lab experimentation with computational and AI-driven methods under a single roof. Its model is built to tackle historically difficult-to-drug cancer targets using a toolkit spanning small molecules, targeted protein degraders, and antibody-drug conjugates.
The company emerged from stealth in 2025 with three programs already in the clinic, including TLN-121 (a BCL6 degrader for lymphomas) and TLN-372 (a pan-KRAS inhibitor). Treeline's combination of computational design and integrated experimental discovery is intended to compress timelines and improve the odds of finding viable candidates against challenging targets.
Treeline has raised approximately $1.1B across multiple rounds from a syndicate of leading investors. In August 2025 it announced a $200M Series A round (with participation from Access Industries, ARCH Venture Partners, OrbiMed, Google Ventures, KKR, Casdin Capital, Fidelity, and others), coinciding with the launch of its first clinical trials.
Founded in 2021 by Loxo Oncology founder Joshua Bilenker (CEO) and former Novartis executive Jeffrey Engelman, Treeline pairs experienced oncology leadership with a modern, computationally enabled discovery engine.